IDXX vs. EXAS

Last updated Jun 4, 2026

IDXX (IDEXX Laboratories, Inc.) and EXAS (Exact Sciences Corporation) are both stocks. Both operate in the Diagnostics & Research industry within the Healthcare sector. At a 0.26 correlation, their price movements are largely independent.

Performance

IDXX vs. EXAS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in IDEXX Laboratories, Inc. (IDXX) and Exact Sciences Corporation (EXAS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

IDXX

• 1D: 1.80%
• 1M: -0.42%
• YTD: -17.12%
• 6M: -22.76%
• 1Y: 6.64%
• 3Y*: 6.00%
• 5Y*: 0.08%
• 10Y*: 20.33%

EXAS

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

IDXX vs. EXAS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
IDXX IDEXX Laboratories, Inc.	-17.12%	63.63%	-25.51%	36.06%	-38.04%	31.73%	91.43%	40.38%	18.95%	33.35%
EXAS Exact Sciences Corporation	3.30%	80.74%	-24.05%	49.42%	-36.39%	-41.26%	43.26%	46.56%	20.10%	293.26%

Correlation

The correlation between IDXX and EXAS is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.15
Correlation (3Y) Calculated over the trailing 3-year period	0.22
Correlation (5Y) Calculated over the trailing 5-year period	0.36
Correlation (10Y) Calculated over the trailing 10-year period	0.38
Correlation (All Time) Calculated using the full available price history since Feb 2, 2001	0.26

The correlation between IDXX and EXAS shifts across timeframes, from 0.15 (1 year) to 0.38 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

EPS IDXX : $18.08 EXAS : -$1.10
PS Ratio IDXX : 7.64 EXAS : 6.12
Total Revenue (TTM) IDXX : $4.45B EXAS : $3.25B
Gross Profit (TTM) IDXX : $2.76B EXAS : $2.26B
EBITDA (TTM) IDXX : $1.52B EXAS : $42.61M

Return for Risk

IDXX vs. EXAS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IDXX

IDXX Risk / Return Rank: 46
IDXX Sharpe Ratio Rank: 46
IDXX Sortino Ratio Rank: 46
IDXX Omega Ratio Rank: 45
IDXX Calmar Ratio Rank: 45
IDXX Martin Ratio Rank: 45

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IDXX vs. EXAS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for IDEXX Laboratories, Inc. (IDXX) and Exact Sciences Corporation (EXAS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IDXX	EXAS	Difference
Sharpe ratio Return per unit of total volatility	0.16	—	—
Sortino ratio Return per unit of downside risk	0.69	—	—
Omega ratio Gain probability vs. loss probability	1.08	—	—
Calmar ratio Return relative to maximum drawdown	0.21	—	—
Martin ratio Return relative to average drawdown	0.45	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	IDXX	EXAS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.16	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.00	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.62	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.51	—	—

Drawdowns

Drawdown Indicators

	IDXX	EXAS	Difference
Max Drawdown Largest peak-to-trough decline	-81.42%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-31.04%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-37.41%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-54.00%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-54.00%	—	—
Current Drawdown Current decline from peak	-26.86%	—	—
Average Drawdown Average peak-to-trough decline	-21.00%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	14.74%	—	—

Volatility

Volatility by Period

	IDXX	EXAS	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.11%	—	—
Volatility (6M) Calculated over the trailing 6-month period	19.92%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	41.43%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	35.28%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	33.01%	—	—

Dividends

IDXX vs. EXAS - Dividend Comparison

Neither IDXX nor EXAS has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

IDXX vs. EXAS - Profitability Comparison

The chart below illustrates the profitability comparison between IDEXX Laboratories, Inc. and Exact Sciences Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

IDXX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, IDEXX Laboratories, Inc. reported a gross profit of 722.74M and revenue of 1.14B. Therefore, the gross margin over that period was 63.4%.

EXAS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported a gross profit of 615.83M and revenue of 878.38M. Therefore, the gross margin over that period was 70.1%.

IDXX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, IDEXX Laboratories, Inc. reported an operating income of 362.59M and revenue of 1.14B, resulting in an operating margin of 31.8%.

EXAS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported an operating income of -76.68M and revenue of 878.38M, resulting in an operating margin of -8.7%.

IDXX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, IDEXX Laboratories, Inc. reported a net income of 278.45M and revenue of 1.14B, resulting in a net margin of 24.4%.

EXAS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported a net income of -85.96M and revenue of 878.38M, resulting in a net margin of -9.8%.

Frequently Asked Questions

Can I hold both IDXX and EXAS in my portfolio?

IDXX and EXAS have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.